Johnson & Johnson's Schizophrenia Treatment Shows Long-Term Safety/Tolerability

(December 12, 2007) -- NEW YORK, Dec. 12, 2007 (Thomson Financial delivered by Newstex) -- Johnson & Johnson Wednesday said its schizophrenia anti-psychotic treatment, Invega extended-release tablets, showed favorable long-term safety and tolerability during a one-year study.

On average, the company-sponsored study found patient symptom scores improved or were stable.

Symptoms of schizophrenia were reduced in patients that transitioned from placebo to Invega and were maintained in those that were previously on Invega.

Discontinuations resulting from treatment-related adverse events were 6%, as were discontinuations resulting from serious treatment-related events.

'This long-term extension trial adds to the body of knowledge regarding the safety of Invega in the longer-term treatment of schizophrenia. The study also suggests that symptom control is maintained over time,' said a principal investigator involved with the 235-patient study.

Shares of the New Brunswick, N.J.-based health care products company closed Tuesday at $67.55.

advertisement

Melinda Peer Copyright Thomson Financial News Limited 2007. All rights reserved.

The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.

Source: Thomson Financial News Limited

Last updated: 12/07

top ~ next ~ news table of contents ~ send page to a friend

We subscribe to the HONcode principles. Verify here.